Polycythemia vera
- 16 March 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Internal and Emergency Medicine
- Vol. 5 (5), 375-384
- https://doi.org/10.1007/s11739-010-0369-6
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia veraExperimental Hematology, 2009
- Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?Blood, 2009
- The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia veraHaematologica, 2009
- Mutation inTET2in Myeloid CancersNew England Journal of Medicine, 2009
- Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolismJournal of Thrombosis and Haemostasis, 2008
- Role of JAK2 in the pathogenesis and therapy of myeloproliferative disordersNature Reviews Cancer, 2007
- Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disordersJournal of Thrombosis and Haemostasis, 2007
- The treatment of polycythaemia vera: an update in the JAK2 eraInternal and Emergency Medicine, 2007
- JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic ErythrocytosisNew England Journal of Medicine, 2007
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005